Unknown PHASE3 INTERVENTIONAL NCT00027768

Radioactive Iodine in Treating Patients Who Have Undergone Surgery for Liver Cancer

Randomised Trial of Adjuvant Hepatic Intra-Arterial Iodine-131-Lipiodol Following Curative Resection of Hepatocellular Carcinoma

Sponsor: National Medical Research Council (NMRC), Singapore

Conditions Liver Cancer

Interventions adjuvant therapy iodine I 131 ethiodized oil

Updated 5 times since 2017 Last updated: Sep 19, 2013 Started: Jun 30, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Liver Cancer and is currently ongoing. National Medical Research Council (NMRC), Singapore leads this study, which shows 5 recorded versions since 2001 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE3
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE3

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE3
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE3
Jan 2017 — Jun 2018 [monthly]

Unknown Status PHASE3

First recorded

Jun 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Medical Research Council (NMRC), Singapore

Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Singapore, Singapore